Humoral signatures of MOG-antibody-associated disease track with age and disease activity
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we...
Authors: | |
---|---|
Division/Institute: | FB 05: Medizinische Fakultät |
Document types: | Article |
Media types: | Text |
Publication date: | 2023 |
Date of publication on miami: | 05.04.2023 |
Modification date: | 05.04.2023 |
Edition statement: | [Electronic ed.] |
Source: | Cell Reports Medicine 4 (2023) 2, 100913, 1-9, e1-e3 |
Subjects: | humoral signatures; myelin oligodendrocyte glycoprotein; MOGAD; antibody; Fc gamma receptors; demyelination |
DDC Subject: | 610: Medizin und Gesundheit |
License: | CC BY-NC-ND 4.0 |
Language: | Englisch |
Funding: | Finanziert durch den Open-Access-Publikationsfonds der Westfälischen Wilhelms-Universität Münster (WWU Münster). |
Format: | PDF document |
URN: | urn:nbn:de:hbz:6-50079452027 |
Other Identifiers: | DOI: 10.17879/50079453116 |
Permalink: | https://nbn-resolving.de/urn:nbn:de:hbz:6-50079452027 |
Related records: |
|
Digital documents: | 10.1016_j.xcrm.2022.100913.pdf |
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we use a systems-level approach combined with high-dimensional characterization of Ab-associated immune features to deeply profile humoral immune responses in 123 patients with MOGAD. We show that age is a major determinant for MOG-antibody-related immune signatures. Unsupervised clustering additionally identifies two dominant immunological endophenotypes of MOGAD. The pro-inflammatory endophenotype characterized by increased binding affinities for activating Fcγ receptors (FcγRs), capacity to activate innate immune cells, and decreased frequencies of galactosylated and sialylated immunoglobulin G (IgG) glycovariants is associated with clinically active disease. Our data support the concept that FcγR-mediated effector functions control the pathogenicity of MOG-specific IgG and suggest that FcγR-targeting therapies should be explored for their therapeutic potential in MOGAD.